T1	tradename 112 119	PEGASYS
T3	tradename 181 189	PEGASYS.
T5	tradename 192 199	PEGASYS
T7	nanoparticle 201 223	peginterferon alfa-2a)
T9	routeofadministration 239 251	subcutaneous
T11	fdaapprovaldate 279 283	2002
T13	adversereaction 458 474	neuropsychiatric
T15	adversereaction 476 486	autoimmune
T17	adversereaction 488 496	ischemic
T19	adversereaction 502 523	infectious disorders.
T21	co-administereddrug 835 844	Ribavirin
T23	tradename 935 942	PEGASYS
T25	indication 987 1012	Chronic Hepatitis C (CHC)
T27	tradename 1172 1179	PEGASYS
T29	indication 1210 1213	CHC
T31	indication 1350 1403	HBeAg positive and HBeAg negative chronic hepatitis B
T33	tradename 1539 1546	PEGASYS
T35	routeofadministration 1566 1578	subcutaneous
T37	indication 1617 1620	CHC
T39	indication 1624 1649	chronic hepatitis B (CHB)
T41	tradename 1651 1658	PEGASYS
T43	dose 1671 1678	180 mcg
T45	frequency 1679 1687	per week
T47	indication 1853 1856	CHC
T49	tradename 1858 1865	PEGASYS
T51	dose 1878 1893	180 mcg/1.73 m2
T53	frequency 1900 1908	per week
T55	co-administereddrug 1930 1939	ribavirin
T57	tradename 2819 2826	Pegasys
T59	co-administereddrug 2852 2861	Ribavirin
T61	co-administereddrug 2988 2997	Ribavirin
T63	tradename 3174 3181	PEGASYS
T65	adversereaction 3364 3390	Neuropsychiatric reactions
T67	adversereaction 3398 3422	Cardiovascular disorders
T69	adversereaction 3430 3453	Bone marrow suppression
T71	adversereaction 3461 3495	Autoimmune and endocrine disorders
T73	adversereaction 3526 3540	hyperglycemia)
T75	adversereaction 3553 3577	Ophthalmologic disorders
T77	adversereaction 3585 3610	Cerebrovascular disorders
T79	adversereaction 3618 3663	Hepatic decompensation in cirrhotic patients.
T81	adversereaction 3677 3719	 of hepatitis during hepatitis B treatment
T83	adversereaction 3727 3746	Pulmonary disorders
T85	adversereaction 3755 3776	Infections (bacterial
T87	adversereaction 3778 3783	viral
T89	adversereaction 3785 3792	fungal)
T91	adversereaction 3801 3808	Colitis
T93	adversereaction 3813 3825	pancreatitis
T95	adversereaction 3840 3856	Hypersensitivity
T97	adversereaction 3861 3883	serious skin reactions
T99	adversereaction 3894 3918	Stevens-Johnson syndrome
T101	adversereaction 3927 3944	Growth impairment
T103	adversereaction 4000 4021	Peripheral neuropathy
T105	co-administereddrug 4052 4063	telbivudine
T107	adversereaction 4159 4175	fatigue/asthenia
T109	adversereaction 4177 4184	pyrexia
T111	adversereaction 4186 4193	myalgia
T113	adversereaction 4199 4208	headache.
T115	company 4364 4373	Genentech
T117	co-administereddrug 4576 4586	Methadone:
T119	co-administereddrug 4621 4630	methadone
T121	tradename 4736 4743	PEGASYS
T123	co-administereddrug 4747 4756	ribavirin
T125	co-administereddrug 4798 4809	Zidovudine:
T127	tradename 4863 4870	PEGASYS
T129	co-administereddrug 4878 4888	ribavirin(
T131	adversereaction 5060 5076	Neuropsychiatric
T133	adversereaction 5078 5085	cardiac
T135	adversereaction 5091 5128	systemic (flu-like) adverse reactions
T137	tradename 5368 5375	PEGASYS
T139	indication 5470 5490	Chronic Hepatitis B:
T141	indication 5782 5801	Chronic Hepatitis C
T143	indication 5806 5825	Chronic Hepatitis B
T145	indication 5901 5904	CHC
T147	indication 5934 5937	CHC
T149	indication 5943 5962	Chronic Hepatitis B
T151	co-administereddrug 6127 6136	Ribavirin
T153	adversereaction 6142 6158	Neuropsychiatric
T155	adversereaction 6164 6188	Cardiovascular Disorders
T157	adversereaction 6194 6217	Bone Marrow Suppression
T159	adversereaction 6223 6243	Autoimmune Disorders
T161	adversereaction 6249 6268	Endocrine Disorders
T163	adversereaction 6274 6298	Ophthalmologic Disorders
T165	adversereaction 6304 6329	Cerebrovascular Disorders
T167	adversereaction 6335 6350	Hepatic Failure
T169	adversereaction 6355 6378	Hepatitis Exacerbations
T171	adversereaction 6385 6404	Pulmonary Disorders
T173	adversereaction 6411 6421	Infections
T175	adversereaction 6428 6435	Colitis
T177	adversereaction 6442 6454	Pancreatitis
T179	adversereaction 6461 6477	Hypersensitivity
T181	adversereaction 6484 6500	Impact on Growth
T183	adversereaction 6529 6550	Peripheral Neuropathy
T185	co-administereddrug 6745 6757	Theophylline
T187	co-administereddrug 6763 6772	Methadone
T189	indication 6988 7007	Chronic Hepatitis B
T191	indication 7270 7289	Chronic Hepatitis C
T193	tradename 7311 7319	PEGASYS/
T195	co-administereddrug 7319 7326	COPEGUS
T197	indication 7352 7371	Chronic Hepatitis C
T199	indication 7398 7402	CHC/
T201	tradename 7418 7425	PEGASYS
T203	tradename 7442 7450	PEGASYS/
T205	co-administereddrug 7450 7457	COPEGUS
T207	indication 7486 7505	Chronic Hepatitis C
T209	tradename 7526 7533	PEGASYS
T211	indication 7551 7570	Chronic Hepatitis B
T213	tradename 7588 7595	PEGASYS
T215	tradename 7923 7930	PEGASYS
T217	nanoparticle 7932 7954	peginterferon alfa-2a)
T219	adversereaction 8005 8021	neuropsychiatric
T221	adversereaction 8023 8033	autoimmune
T223	adversereaction 8035 8043	ischemic
T225	adversereaction 8049 8070	infectious disorders.
T227	tradename 8343 8350	PEGASYS
T229	indication 8514 8533	Chronic Hepatitis C
T231	tradename 8534 8541	PEGASYS
T233	indication 8674 8699	chronic hepatitis C (CHC)
T235	tradename 8841 8848	PEGASYS
T237	tradename 8890 8897	PEGASYS
T239	co-administereddrug 8918 8927	ribavirin
T241	indication 9007 9010	CHC
T243	tradename 9042 9049	PEGASYS
T245	indication 9115 9118	CHC
T247	tradename 9260 9267	PEGASYS
T249	co-administereddrug 9297 9306	ribavirin
T251	indication 9396 9399	CHC
T253	tradename 9456 9463	PEGASYS
T255	indication 9514 9517	CHC
T257	indication 9606 9631	Chronic Hepatitis B (CHB)
T259	tradename 9632 9639	PEGASYS
T261	indication 9694 9747	HBeAg-positive and HBeAg-negative chronic hepatitis B
T263	tradename 9912 9919	PEGASYS
T265	routeofadministration 9923 9935	subcutaneous
T267	frequency 9946 9957	once weekly
T269	indication 10025 10050	chronic hepatitis C (CHC)
T271	indication 10151 10154	CHC
T273	indication 10219 10244	chronic hepatitis B (CHB)
T275	indication 10302 10305	CHC
T277	tradename 10311 10318	PEGASYS
T279	tradename 10537 10544	PEGASYS
T281	indication 10595 10598	CHC
T283	indication 10733 10736	CHC
T285	indication 10740 10744	CHB:
T287	tradename 11106 11113	PEGASYS
T289	indication 11246 11265	Chronic Hepatitis C
T291	indication 11288 11291	CHC
T293	tradename 11372 11379	PEGASYS
T295	indication 11425 11428	CHC
T297	tradename 11516 11523	PEGASYS
T299	co-administereddrug 11544 11553	ribavirin
T301	tradename 11913 11920	PEGASYS
T303	tradename 12012 12019	PEGASYS
T305	tradename 12136 12143	PEGASYS
T307	indication 12148 12151	CHC
T309	tradename 12191 12198	PEGASYS
T311	tradename 12206 12213	PEGASYS
T313	dose 12240 12247	180 mcg
T315	routeofadministration 12248 12260	subcutaneous
T317	frequency 12291 12302	once weekly
T319	tradename 12456 12463	PEGASYS
T321	indication 12518 12521	CHC
T323	tradename 12704 12711	PEGASYS
T325	co-administereddrug 12716 12725	ribavirin
T327	tradename 12824 12831	PEGASYS
T329	co-administereddrug 12836 12845	ribavirin
T331	tradename 12942 12949	PEGASYS
T333	indication 12987 12990	CHC
T335	tradename 13008 13015	PEGASYS
T337	dose 13026 13033	180 mcg
T339	routeofadministration 13038 13050	subcutaneous
T341	frequency 13081 13106	once weekly for 48 weeks.
T343	indication 13130 13133	CHC
T345	tradename 13171 13178	PEGASYS
T347	indication 13201 13204	CHC
T349	dose 13228 13235	180 mcg
T351	routeofadministration 13236 13250	subcutaneously
T353	tradename 13291 13298	PEGASYS
T355	tradename 13536 13544	PEGASYS)
T357	tradename 13549 13556	PEGASYS
T359	indication 13723 13726	CHC
T361	tradename 13728 13735	PEGASYS
T363	dose 13755 13770	180 mcg/1.73 m2
T365	routeofadministration 13777 13791	subcutaneously
T367	frequency 13792 13803	once weekly
T369	dose 13826 13833	180 mcg
T371	co-administereddrug 14230 14239	ribavirin
T373	indication 14298 14323	Chronic Hepatitis B (CHB)
T375	tradename 14341 14348	PEGASYS
T377	indication 14371 14374	CHB
T379	dose 14378 14385	180 mcg
T381	routeofadministration 14386 14400	subcutaneously
T383	frequency 14401 14412	once weekly
T385	tradename 14601 14608	PEGASYS
T387	tradename 14939 14946	PEGASYS
T389	tradename 15067 15074	PEGASYS
T391	dose 15127 15134	135 mcg
T393	routeofadministration 15135 15149	subcutaneously
T395	frequency 15150 15161	once weekly
T397	dose 15276 15282	90 mcg
T399	routeofadministration 15283 15297	subcutaneously
T401	frequency 15298 15309	once weekly
T403	dose 15386 15392	90 mcg
T405	routeofadministration 15393 15407	subcutaneously
T407	frequency 15408 15419	once weekly
T409	indication 15741 15744	CHC
T411	tradename 15822 15829	PEGASYS
T413	dose 15851 15858	135 mcg
T415	tradename 15933 15940	PEGASYS
T417	tradename 16233 16240	PEGASYS
T419	dose 16244 16251	135 mcg
T421	tradename 16298 16305	PEGASYS
T423	tradename 16648 16655	PEGASYS
T425	tradename 16882 16889	PEGASYS
T427	tradename 17387 17394	PEGASYS
T429	dose 17415 17422	135 mcg
T431	dose 17424 17439	135 mcg/1.73 m2
T433	dose 17473 17479	90 mcg
T435	frequency 17480 17491	once weekly
T437	dose 17493 17507	90 mcg/1.73 m2
T439	tradename 17558 17565	PEGASYS
T441	dose 17576 17583	135 mcg
T443	dose 17585 17600	135 mcg/1.73 m2
T445	dose 17634 17640	90 mcg
T447	dose 17642 17656	90 mcg/1.73 m2
T449	frequency 17687 17698	once weekly
T451	tradename 18011 18018	PEGASYS
T453	tradename 18052 18059	PEGASYS
T455	tradename 18276 18283	PEGASYS
T457	indication 18415 18419	CHC.
T459	tradename 18442 18449	PEGASYS
T461	tradename 18581 18588	PEGASYS
T463	dose 18680 18695	135 mcg/1.73 m2
T465	dose 18833 18848	135 mcg/1.73 m2
T467	dose 18945 18960	135 mcg/1.73 m2
T469	dose 19067 19081	90 mcg/1.73 m2
T471	dose 19168 19183	135 mcg/1.73 m2
T473	dose 19329 19343	90 mcg/1.73 m2
T475	tradename 19760 19767	PEGASYS
T477	tradename 20323 20330	PEGASYS
T479	tradename 20418 20425	PEGASYS
T481	dose 20453 20460	180 mcg
T483	frequency 20461 20472	once weekly
T485	dose 20532 20539	135 mcg
T487	frequency 20540 20551	once weekly
T489	dose 20612 20619	135 mcg
T491	frequency 20620 20631	once weekly
T493	tradename 20700 20707	PEGASYS
T495	dose 20731 20737	90 mcg
T497	frequency 20738 20749	once weekly
T499	tradename 20830 20837	PEGASYS
T501	routeofadministration 20924 20936	subcutaneous
T503	routeofadministration 20962 20976	subcutaneously
T505	tradename 20994 21001	PEGASYS
T507	tradename 21107 21114	PEGASYS
T509	tradename 21294 21301	PEGASYS
T511	dose 21446 21449	180
T513	dose 21451 21454	135
T515	dose 21456 21465	or 90 mcg
T517	frequency 21466 21478	once weekly)
T519	tradename 21511 21518	PEGASYS
T521	tradename 21671 21678	PEGASYS
T523	tradename 21700 21707	PEGASYS
T525	tradename 21716 21723	PEGASYS
T527	tradename 22268 22275	PEGASYS
T529	tradename 22472 22479	PEGASYS
T531	tradename 22779 22786	PEGASYS
T533	tradename 23019 23026	PEGASYS
T535	tradename 23172 23179	PEGASYS
T537	co-administereddrug 23207 23216	ribavirin
T539	co-administereddrug 23462 23471	ribavirin
T541	co-administereddrug 23696 23715	Ribavirin Ribavirin
T543	tradename 23873 23880	PEGASYS
T545	co-administereddrug 23885 23894	ribavirin
T547	co-administereddrug 23916 23925	Ribavirin
T549	co-administereddrug 24357 24366	ribavirin
T551	adversereaction 24383 24409	Neuropsychiatric Reactions
T553	adversereaction 24437 24463	neuropsychiatric reactions
T555	tradename 24516 24523	PEGASYS
T557	adversereaction 24536 24543	suicide
T559	adversereaction 24545 24562	suicidal ideation
T561	adversereaction 24564 24582	homicidal ideation
T563	adversereaction 24584 24594	depression
T565	adversereaction 24596 24621	relapse of drug addiction
T567	adversereaction 24627 24641	drug overdose.
T569	tradename 24728 24735	PEGASYS
T571	adversereaction 24824 24855	Neuropsychiatric adverse events
T573	adversereaction 24905 24924	aggressive behavior
T575	adversereaction 24926 24935	psychoses
T577	adversereaction 24937 24951	hallucinations
T579	adversereaction 24953 24970	bipolar disorders
T581	adversereaction 24976 24982	mania.
T583	adversereaction 25388 25425	Cardiovascular Disorders Hypertension
T585	adversereaction 25427 25455	supraventricular arrhythmias
T587	adversereaction 25457 25467	chest pain
T589	adversereaction 25473 25494	myocardial infarction
T591	tradename 25539 25547	PEGASYS.
T593	tradename 25548 25555	PEGASYS
T595	tradename 25794 25802	PEGASYS/
T597	co-administereddrug 25802 25811	ribavirin
T599	co-administereddrug 25817 25826	ribavirin
T601	adversereaction 25858 25881	Bone Marrow Suppression
T603	tradename 25882 25889	PEGASYS
T605	adversereaction 25947 25958	cytopenias.
T607	co-administereddrug 25959 25968	Ribavirin
T609	tradename 26055 26063	PEGASYS.
T611	adversereaction 26119 26135	aplastic anemia.
T613	co-administereddrug 26253 26262	ribavirin
T615	tradename 26290 26298	PEGASYS/
T617	co-administereddrug 26298 26307	ribavirin
T619	tradename 26506 26513	PEGASYS
T621	adversereaction 26686 26704	Severe neutropenia
T623	adversereaction 26709 26725	thrombocytopenia
T625	adversereaction 26829 26847	serious infections
T627	adversereaction 26851 26859	bleeding
T629	adversereaction 26892 26904	Pancytopenia
T631	adversereaction 26963 26986	bone marrow suppression
T633	nanoparticle 27093 27114	pegylated interferon/
T635	co-administereddrug 27114 27123	ribavirin
T637	co-administereddrug 27128 27141	azathioprine.
T639	adversereaction 27184 27197	myelotoxicity
T641	co-administereddrug 27295 27307	azathioprine
T643	tradename 27373 27380	PEGASYS
T645	co-administereddrug 27382 27391	ribavirin
T647	co-administereddrug 27397 27409	azathioprine
T649	adversereaction 27437 27449	pancytopenia
T651	nanoparticle 27455 27476	pegylated interferon/
T653	co-administereddrug 27476 27485	ribavirin
T655	adversereaction 27550 27570	Autoimmune Disorders
T657	adversereaction 27603 27623	autoimmune disorders
T659	adversereaction 27634 27642	myositis
T661	adversereaction 27644 27653	hepatitis
T663	adversereaction 27655 27690	thrombotic thrombocytopenic purpura
T665	adversereaction 27692 27727	idiopathic thrombocytopenic purpura
T667	adversereaction 27729 27738	psoriasis
T669	adversereaction 27740 27760	rheumatoid arthritis
T671	adversereaction 27762 27784	interstitial nephritis
T673	adversereaction 27786 27797	thyroiditis
T675	adversereaction 27803 27831	systemic lupus erythematosus
T677	tradename 27891 27898	PEGASYS
T679	adversereaction 27991 28010	Endocrine Disorders
T681	tradename 28012 28019	PEGASYS
T683	adversereaction 28041 28055	hypothyroidism
T685	adversereaction 28060 28090	hyperthyroidism. Hyperglycemia
T687	adversereaction 28092 28104	hypoglycemia
T689	adversereaction 28110 28127	diabetes mellitus
T691	tradename 28183 28191	PEGASYS.
T693	tradename 28300 28307	PEGASYS
T695	tradename 28444 28451	PEGASYS
T697	adversereaction 28466 28490	Ophthalmologic Disorders
T699	adversereaction 28492 28518	Decrease or loss of vision
T701	adversereaction 28520 28531	retinopathy
T703	adversereaction 28542 28555	macular edema
T705	adversereaction 28557 28590	retinal artery or vein thrombosis
T707	adversereaction 28592 28611	retinal hemorrhages
T709	adversereaction 28616 28633	cotton wool spots
T711	adversereaction 28635 28649	optic neuritis
T713	adversereaction 28651 28662	papilledema
T715	adversereaction 28667 28692	serous retinal detachment
T717	tradename 28737 28744	PEGASYS
T719	tradename 29105 29112	PEGASYS
T721	adversereaction 29218 29243	Cerebrovascular Disorders
T723	adversereaction 29245 29292	Ischemic and hemorrhagic cerebrovascular events
T725	activeingredient 29337 29358	interferon alfa-based
T727	tradename 29380 29388	PEGASYS.
T729	activeingredient 29623 29644	interferon alfa-based
T731	adversereaction 29724 29739	Hepatic Failure
T733	adversereaction 29744 29767	Hepatitis Exacerbations
T735	indication 29768 29793	Chronic hepatitis C (CHC)
T737	adversereaction 29836 29858	hepatic decompensation
T739	adversereaction 29863 29868	death
T741	tradename 29916 29924	PEGASYS.
T743	indication 29935 29938	CHC
T745	activeingredient 30027 30045	interferon alfa-2a
T747	co-administereddrug 30062 30071	ribavirin
T749	indication 30243 30247	CHC/
T751	tradename 30705 30713	PEGASYS/
T753	co-administereddrug 30713 30722	ribavirin
T755	adversereaction 30838 30864	Exacerbations of hepatitis
T757	indication 30872 30883	hepatitis B
T759	indication 30991 31010	Chronic hepatitis B
T761	adversereaction 31042 31085	acute exacerbations (flares) of hepatitis B
T763	tradename 31168 31175	PEGASYS
T765	tradename 31329 31336	PEGASYS
T767	adversereaction 31376 31401	liver test abnormalities.
T769	tradename 31494 31501	PEGASYS
T771	tradename 31638 31645	PEGASYS
T773	tradename 31732 31739	PEGASYS
T775	adversereaction 31848 31867	Pulmonary Disorders
T777	adversereaction 31869 31876	Dyspnea
T779	adversereaction 31878 31899	pulmonary infiltrates
T781	adversereaction 31901 31910	pneumonia
T783	adversereaction 31912 31936	bronchiolitis obliterans
T785	adversereaction 31938 31962	interstitial pneumonitis
T787	adversereaction 31964 31986	pulmonary hypertension
T789	adversereaction 31991 32002	sarcoidosis
T791	adversereaction 32022 32041	respiratory failure
T793	adversereaction 32057 32063	deaths
T795	tradename 32097 32104	PEGASYS
T797	adversereaction 32148 32167	respiratory failure
T799	tradename 32215 32222	PEGASYS
T801	adversereaction 32289 32310	pulmonary infiltrates
T803	adversereaction 32314 32344	pulmonary function impairment.
T805	adversereaction 32422 32432	Infections
T807	adversereaction 32439 32444	fever
T809	adversereaction 32570 32575	fever
T811	adversereaction 32651 32679	severe infections (bacterial
T813	adversereaction 32681 32686	viral
T815	adversereaction 32688 32698	or fungal)
T817	tradename 32781 32789	PEGASYS.
T819	adversereaction 32934 32941	Colitis
T821	adversereaction 32943 32986	Ulcerative and hemorrhagic/ischemic colitis
T823	adversereaction 33080 33094	Abdominal pain
T825	adversereaction 33096 33111	bloody diarrhea
T827	adversereaction 33117 33122	fever
T829	adversereaction 33157 33165	colitis.
T831	tradename 33166 33173	PEGASYS
T833	adversereaction 33240 33247	colitis
T835	adversereaction 33331 33343	Pancreatitis
T837	adversereaction 33345 33357	Pancreatitis
T839	co-administereddrug 33417 33426	ribavirin
T841	tradename 33438 33446	PEGASYS/
T843	co-administereddrug 33446 33455	ribavirin
T845	adversereaction 33511 33523	pancreatitis
T847	tradename 33538 33546	PEGASYS/
T849	co-administereddrug 33546 33555	ribavirin
T851	adversereaction 33606 33619	pancreatitis.
T853	adversereaction 33626 33642	Hypersensitivity
T855	adversereaction 33657 33683	hypersensitivity reactions
T857	adversereaction 33691 33700	urticaria
T859	adversereaction 33702 33712	angioedema
T861	adversereaction 33714 33733	bronchoconstriction
T863	adversereaction 33739 33751	anaphylaxis)
T865	co-administereddrug 33799 33808	ribavirin
T867	tradename 33856 33864	PEGASYS/
T869	co-administereddrug 33864 33873	ribavirin
T871	adversereaction 33953 33975	Serious skin reactions
T873	adversereaction 33986 34011	vesiculobullous eruptions
T875	adversereaction 34042 34066	Stevens-Johnson Syndrome
T877	adversereaction 34068 34094	erythema multiforme major)
T879	adversereaction 34152 34174	exfoliative dermatitis
T881	adversereaction 34176 34189	erythroderma)
T883	tradename 34231 34238	PEGASYS
T885	co-administereddrug 34256 34266	ribavirin.
T887	adversereaction 34309 34330	severe skin reactions
T889	adversereaction 34393 34409	Impact on Growth
T891	tradename 34483 34490	PEGASYS
T893	co-administereddrug 34496 34505	ribavirin
T895	adversereaction 35113 35134	Peripheral Neuropathy
T897	adversereaction 35136 35157	Peripheral neuropathy
T899	co-administereddrug 35230 35242	telbivudine.
T901	adversereaction 35300 35321	peripheral neuropathy
T903	co-administereddrug 35363 35374	telbivudine
T905	tradename 35379 35386	PEGASYS
T907	co-administereddrug 35402 35413	telbivudine
T909	co-administereddrug 35449 35460	telbivudine
T911	indication 35514 35533	chronic hepatitis B
T913	tradename 35604 35611	PEGASYS
T915	tradename 35615 35622	PEGASYS
T917	tradename 35928 35936	PEGASYS/
T919	co-administereddrug 35936 35946	ribavirin.
T921	tradename 36807 36814	PEGASYS
T923	indication 37060 37063	CHC
T925	indication 37611 37614	CHC
T927	indication 37754 37757	CHC
T929	tradename 37898 37905	PEGASYS
T931	dose 37918 37925	180 mcg
T933	co-administereddrug 37969 37977	COPEGUS[
T935	tradename 38105 38112	PEGASYS
T937	co-administereddrug 38117 38124	COPEGUS
T939	adversereaction 38133 38143	depression
T941	adversereaction 38145 38152	suicide
T943	adversereaction 38154 38184	relapse of drug abuse/overdose
T945	adversereaction 38190 38210	bacterial infections
T947	adversereaction 38259 38290	Hepatic decompensation occurred
T949	indication 38309 38313	CHC/
T951	indication 38705 38716	hepatitis C
T953	indication 38783 38786	CHC
T955	indication 38823 38827	CHC/
T957	tradename 38850 38857	PEGASYS
T959	co-administereddrug 38887 38895	COPEGUS.
T961	indication 38946 38949	CHC
T963	indication 38960 38964	CHC/
T965	adversereaction 38973 38992	bacterial infection
T967	adversereaction 39000 39006	sepsis
T969	adversereaction 39008 39021	osteomyelitis
T971	adversereaction 39023 39035	endocarditis
T973	adversereaction 39037 39051	pyelonephritis
T975	adversereaction 39053 39063	pneumonia)
T977	adversereaction 39130 39137	suicide
T979	adversereaction 39139 39156	suicidal ideation
T981	adversereaction 39170 39177	anxiety
T983	adversereaction 39179 39189	drug abuse
T985	adversereaction 39194 39207	drug overdose
T987	adversereaction 39209 39215	angina
T989	adversereaction 39217 39236	hepatic dysfunction
T991	adversereaction 39238 39249	fatty liver
T993	adversereaction 39251 39262	cholangitis
T995	adversereaction 39264 39274	arrhythmia
T997	adversereaction 39276 39293	diabetes mellitus
T999	adversereaction 39295 39315	autoimmune phenomena
T1001	adversereaction 39323 39338	hyperthyroidism
T1003	adversereaction 39340 39354	hypothyroidism
T1005	adversereaction 39356 39367	sarcoidosis
T1007	adversereaction 39369 39397	systemic lupus erythematosus
T1009	adversereaction 39399 39420	rheumatoid arthritis)
T1011	adversereaction 39433 39443	neuropathy
T1013	adversereaction 39445 39460	aplastic anemia
T1015	adversereaction 39462 39474	peptic ulcer
T1017	adversereaction 39476 39501	gastrointestinal bleeding
T1019	adversereaction 39503 39515	pancreatitis
T1021	adversereaction 39517 39524	colitis
T1023	adversereaction 39526 39539	corneal ulcer
T1025	adversereaction 39541 39559	pulmonary embolism
T1027	adversereaction 39561 39565	coma
T1029	adversereaction 39567 39575	myositis
T1031	adversereaction 39577 39596	cerebral hemorrhage
T1033	adversereaction 39598 39633	thrombotic thrombocytopenic purpura
T1035	adversereaction 39635 39653	psychotic disorder
T1037	adversereaction 39659 39673	hallucination.
T1039	adversereaction 39843 39864	psychiatric reactions
T1041	adversereaction 39876 39886	depression
T1043	adversereaction 39888 39896	insomnia
T1045	adversereaction 39898 39910	irritability
T1047	adversereaction 39912 39919	anxiety
T1049	adversereaction 39925 39942	flu-like symptoms
T1051	adversereaction 39951 39958	fatigue
T1053	adversereaction 39960 39967	pyrexia
T1055	adversereaction 39969 39976	myalgia
T1057	adversereaction 39978 39986	headache
T1059	adversereaction 39992 39999	rigors.
T1061	adversereaction 40029 40037	anorexia
T1063	adversereaction 40039 40045	nausea
T1065	adversereaction 40050 40058	vomiting
T1067	adversereaction 40060 40068	diarrhea
T1069	adversereaction 40070 40081	arthralgias
T1071	adversereaction 40083 40107	injection site reactions
T1073	adversereaction 40109 40117	alopecia
T1075	adversereaction 40123 40132	pruritus.
T1077	tradename 40233 40240	PEGASYS
T1079	tradename 40257 40265	PEGASYS/
T1081	co-administereddrug 40265 40284	COPEGUS combination
T1083	indication 40326 40329	CHC
T1085	tradename 40387 40394	PEGASYS
T1087	co-administereddrug 40431 40438	COPEGUS
T1089	indication 40468 40472	CHC/
T1091	adversereaction 40579 40590	psychiatric
T1093	adversereaction 40592 40609	flu-like syndrome
T1095	adversereaction 40617 40625	lethargy
T1097	adversereaction 40627 40634	fatigue
T1099	adversereaction 40636 40645	headache)
T1101	adversereaction 40722 40738	thrombocytopenia
T1103	adversereaction 40740 40751	neutropenia
T1105	adversereaction 40757 40764	anemia)
T1107	indication 40796 40799	CHC
T1109	indication 40803 40807	CHC/
T1111	tradename 40836 40843	PEGASYS
T1113	co-administereddrug 40851 40858	COPEGUS
T1115	tradename 40917 40924	PEGASYS
T1117	indication 40928 40931	CHC
T1119	indication 40936 40940	CHC/
T1121	adversereaction 40961 40972	neutropenia
T1123	adversereaction 41005 41021	thrombocytopenia
T1125	co-administereddrug 41097 41104	COPEGUS
T1127	indication 41108 41111	CHC
T1129	indication 41116 41120	CHC/
T1131	adversereaction 41137 41143	anemia
T1133	tradename 41173 41180	PEGASYS
T1135	dose 41227 41234	1000 mg
T1137	dose 41238 41245	1200 mg
T1139	co-administereddrug 41246 41253	COPEGUS
T1141	dose 41299 41305	800 mg
T1143	co-administereddrug 41306 41313	COPEGUS
T1145	co-administereddrug 41328 41335	COPEGUS
T1147	dose 41382 41389	1000 mg
T1149	dose 41393 41400	1200 mg
T1151	co-administereddrug 41401 41408	COPEGUS
T1153	dose 41455 41461	800 mg
T1155	co-administereddrug 41462 41469	COPEGUS
T1157	indication 41485 41504	Chronic hepatitis C
T1159	tradename 41553 41560	PEGASYS
T1161	dose 41565 41571	800 mg
T1163	co-administereddrug 41572 41579	COPEGUS
T1165	tradename 41718 41725	PEGASYS
T1167	co-administereddrug 41744 41751	COPEGUS
T1169	tradename 41859 41866	PEGASYS
T1171	dose 41871 41878	1000 mg
T1173	dose 41882 41889	1200 mg
T1175	co-administereddrug 41890 41898	COPEGUS.
T1177	indication 42078 42097	Chronic Hepatitis C
T1179	indication 42153 42156	CHC
T1181	indication 42191 42194	CHC
T1183	tradename 42238 42245	PEGASYS
T1185	dose 42246 42253	180 mcg
T1187	dose 42286 42292	3 MIU*
T1189	dose 42296 42304	6/3 MIU*
T1191	tradename 42333 42340	PEGASYS
T1193	dose 42341 42348	180 mcg
T1195	dose 42351 42358	1000 mg
T1197	dose 42362 42369	1200 mg
T1199	co-administereddrug 42370 42377	COPEGUS
T1201	dose 42400 42407	1000 mg
T1203	dose 42411 42418	1200 mg
T1205	adversereaction 42501 42524	Injection site reaction
T1207	adversereaction 42538 42557	Endocrine Disorders
T1209	adversereaction 42559 42573	Hypothyroidism
T1211	adversereaction 42583 42600	Flu-like Symptoms
T1213	indication 42617 42620	CHC
T1215	indication 42655 42658	CHC
T1217	tradename 42702 42709	PEGASYS
T1219	dose 42710 42717	180 mcg
T1221	dose 42749 42755	3 MIU*
T1223	dose 42759 42767	6/3 MIU*
T1225	tradename 42795 42802	PEGASYS
T1227	dose 42803 42810	180 mcg
T1229	dose 42813 42820	1000 mg
T1231	dose 42824 42831	1200 mg
T1233	co-administereddrug 42832 42839	COPEGUS
T1235	dose 42862 42869	1000 mg
T1237	dose 42873 42880	1200 mg
T1239	adversereaction 42935 42951	Fatigue/Asthenia
T1241	adversereaction 42965 42972	Pyrexia
T1243	adversereaction 42986 42992	Rigors
T1245	adversereaction 43006 43010	Pain
T1247	adversereaction 43040 43055	Nausea/Vomiting
T1249	adversereaction 43068 43076	Diarrhea
T1251	adversereaction 43089 43103	Abdominal pain
T1253	adversereaction 43114 43123	Dry mouth
T1255	adversereaction 43132 43141	Dyspepsia
T1257	adversereaction 43166 43177	Lymphopenia
T1259	adversereaction 43189 43195	Anemia
T1261	adversereaction 43207 43218	Neutropenia
T1263	adversereaction 43230 43246	Thrombocytopenia
T1265	adversereaction 43287 43295	Anorexia
T1267	adversereaction 43297 43312	Weight decrease
T1269	adversereaction 43389 43396	Myalgia
T1271	adversereaction 43410 43420	Arthralgia
T1273	adversereaction 43434 43443	Back pain
T1275	adversereaction 43468 43476	Headache
T1277	adversereaction 43490 43499	Dizziness
T1279	adversereaction 43533 43550	Memory impairment
T1281	indication 43612 43615	CHC
T1283	indication 43650 43653	CHC
T1285	tradename 43697 43704	PEGASYS
T1287	dose 43705 43712	180 mcg
T1289	dose 43744 43750	3 MIU*
T1291	dose 43754 43762	6/3 MIU*
T1293	tradename 43790 43797	PEGASYS
T1295	dose 43798 43805	180 mcg
T1297	dose 43808 43815	1000 mg
T1299	dose 43819 43826	1200 mg
T1301	co-administereddrug 43827 43834	COPEGUS
T1303	dose 43857 43864	1000 mg
T1305	dose 43868 43875	1200 mg
T1307	adversereaction 43942 43975	Irritability/Anxiety/ Nervousness
T1309	adversereaction 43990 43998	Insomnia
T1311	adversereaction 44011 44021	Depression
T1313	adversereaction 44034 44058	Concentration impairment
T1315	adversereaction 44070 44085	Mood alteration
T1317	adversereaction 44134 44141	Dyspnea
T1319	adversereaction 44153 44158	Cough
T1321	adversereaction 44169 44187	Dyspnea exertional
T1323	adversereaction 44235 44243	Alopecia
T1325	adversereaction 44257 44265	Pruritus
T1327	adversereaction 44278 44288	Dermatitis
T1329	adversereaction 44300 44308	Dry skin
T1331	adversereaction 44320 44324	Rash
T1333	adversereaction 44334 44352	Sweating increased
T1335	adversereaction 44362 44368	Eczema
T1337	adversereaction 44396 44410	Vision blurred
T1339	dose 44441 44476	6 million international units (MIU)
T1341	frequency 44477 44518	three times a week for the first 12 weeks
T1343	dose 44531 44560	3 million international units
T1345	frequency 44561 44592	three times a week for 36 weeks
T1347	routeofadministration 44599 44614	subcutaneously.
T1349	tradename 44941 44948	PEGASYS
T1351	co-administereddrug 44978 44985	COPEGUS
T1353	tradename 45327 45334	PEGASYS
T1355	co-administereddrug 45339 45346	COPEGUS
T1357	adversereaction 45352 45374	influenza-like illness
T1359	adversereaction 45382 45415	upper respiratory tract infection
T1361	adversereaction 45423 45431	headache
T1363	adversereaction 45439 45464	gastrointestinal disorder
T1365	adversereaction 45472 45485	skin disorder
T1367	adversereaction 45497 45520	injection-site reaction
T1369	tradename 45565 45572	PEGASYS
T1371	co-administereddrug 45577 45584	COPEGUS
T1373	adversereaction 45649 45659	depression
T1375	adversereaction 45661 45692	psychiatric evaluation abnormal
T1377	adversereaction 45694 45713	transient blindness
T1379	adversereaction 45715 45731	retinal exudates
T1381	adversereaction 45733 45746	hyperglycemia
T1383	adversereaction 45748 45772	type 1 diabetes mellitus
T1385	adversereaction 45778 45785	anemia)
T1387	tradename 45928 45935	PEGASYS
T1389	co-administereddrug 45941 45948	COPEGUS
T1391	adversereaction 45976 45989	hyperglycemia
T1393	adversereaction 45994 46010	cholecystectomy)
T1395	tradename 46198 46205	PEGASYS
T1397	dose 46206 46220	180 mcg/1.73 m
T1399	co-administereddrug 46229 46236	COPEGUS
T1401	dose 46237 46245	15 mg/kg
T1403	tradename 46254 46261	PEGASYS
T1405	dose 46262 46276	180 mcg/1.73 m
T1407	adversereaction 46361 46383	Influenza like illness
T1409	adversereaction 46390 46413	Injection site reaction
T1411	adversereaction 46420 46427	Fatigue
T1413	adversereaction 46434 46446	Irritability
T1415	adversereaction 46481 46506	Gastrointestinal disorder
T1417	adversereaction 46539 46547	Headache
T1419	adversereaction 46594 46598	Rash
T1421	adversereaction 46605 46613	Pruritus
T1423	adversereaction 46675 46695	Musculoskeletal pain
T1425	adversereaction 46725 46733	Insomnia
T1427	adversereaction 46775 46793	Decreased appetite
T1429	tradename 46977 46984	PEGASYS
T1431	adversereaction 47605 47622	Growth inhibition
T1433	tradename 47717 47724	PEGASYS
T1435	co-administereddrug 47730 47739	ribavirin
T1437	indication 48997 49000	CHC
T1439	tradename 49096 49104	PEGASYS/
T1441	co-administereddrug 49104 49111	COPEGUS
T1443	adversereaction 49268 49279	neutropenia
T1445	adversereaction 49287 49293	anemia
T1447	adversereaction 49301 49317	thrombocytopenia
T1449	adversereaction 49324 49339	weight decrease
T1451	adversereaction 49351 49366	mood alteration
T1453	indication 49374 49393	Chronic Hepatitis B
T1455	tradename 49476 49483	PEGASYS
T1457	indication 49487 49506	chronic hepatitis B
T1459	indication 49535 49538	CHC
T1461	tradename 49539 49546	PEGASYS
T1463	adversereaction 49575 49601	exacerbations of hepatitis
T1465	tradename 49655 49662	PEGASYS
T1467	indication 49687 49698	hepatitis B
T1469	indication 49888 49899	hepatitis B
T1471	adversereaction 49913 49923	infections
T1473	adversereaction 49925 49931	sepsis
T1475	adversereaction 49933 49945	appendicitis
T1477	adversereaction 49947 49959	tuberculosis
T1479	adversereaction 49961 49971	influenza)
T1481	adversereaction 49973 49991	hepatitis B flares
T1483	adversereaction 49997 50033	thrombotic thrombocytopenic purpura.
T1485	adversereaction 50067 50085	anaphylactic shock
T1487	tradename 50190 50198	PEGASYS.
T1489	tradename 50252 50259	PEGASYS
T1491	adversereaction 50302 50309	pyrexia
T1493	adversereaction 50324 50332	headache
T1495	adversereaction 50347 50354	fatigue
T1497	adversereaction 50370 50377	myalgia
T1499	adversereaction 50392 50400	alopecia
T1501	adversereaction 50419 50427	anorexia
T1503	indication 50457 50468	hepatitis B
T1505	tradename 50491 50498	PEGASYS
T1507	tradename 50552 50559	PEGASYS
T1509	tradename 50633 50640	PEGASYS
T1511	adversereaction 50692 50703	neutropenia
T1513	adversereaction 50711 50727	thrombocytopenia
T1515	adversereaction 50739 50752	ALT elevation
T1517	indication 50838 50849	hepatitis B
T1519	tradename 50918 50925	PEGASYS
T1521	indication 50938 50941	CHC
T1523	indication 50970 50981	hepatitis C
T1525	tradename 51084 51091	PEGASYS
T1527	co-administereddrug 51128 51136	COPEGUS.
T1529	adversereaction 51173 51184	neutropenia
T1531	indication 51233 51236	CHC
T1533	indication 51257 51261	CHC/
T1535	tradename 51284 51291	PEGASYS
T1537	co-administereddrug 51328 51336	COPEGUS.
T1539	tradename 51353 51360	PEGASYS
T1541	adversereaction 51370 51381	neutropenia
T1543	tradename 51420 51427	PEGASYS
T1545	tradename 51470 51478	PEGASYS/
T1547	co-administereddrug 51478 51485	COPEGUS
T1549	indication 51515 51519	CHC/
T1551	adversereaction 51583 51595	neutropenia.
T1553	indication 51625 51628	CHC
T1555	indication 51654 51658	CHC/
T1557	tradename 51695 51702	PEGASYS
T1559	tradename 51978 51985	PEGASYS
T1561	co-administereddrug 51991 52010	COPEGUS combination
T1563	indication 52079 52082	CHC
T1565	indication 52094 52098	CHC/
T1567	indication 52145 52148	CHC
T1569	indication 52170 52174	CHC/
T1571	indication 52187 52198	hepatitis C
T1573	adversereaction 52208 52219	lymphopenia
T1575	tradename 52292 52299	PEGASYS
T1577	co-administereddrug 52304 52311	COPEGUS
T1579	adversereaction 52326 52337	lymphopenia
T1581	tradename 52448 52455	PEGASYS
T1583	co-administereddrug 52460 52467	COPEGUS
T1585	indication 52599 52602	CHC
T1587	tradename 52790 52797	PEGASYS
T1589	co-administereddrug 52803 52810	COPEGUS
T1591	indication 53011 53022	hepatitis C
T1593	indication 53068 53071	CHC
T1595	indication 53092 53096	CHC/
T1597	tradename 53122 53129	PEGASYS
T1599	indication 53211 53214	CHC
T1601	indication 53235 53239	CHC/
T1603	co-administereddrug 53287 53294	COPEGUS
T1605	adversereaction 53354 53370	thrombocytopenia
T1607	indication 53422 53425	CHC
T1609	indication 53436 53440	CHC/
T1611	indication 53567 53578	hepatitis C
T1613	adversereaction 53781 53787	anemia
T1615	indication 53894 53897	CHC
T1617	indication 53917 53921	CHC/
T1619	tradename 53944 53951	PEGASYS
T1621	adversereaction 53987 53993	anemia
T1623	co-administereddrug 53997 54004	COPEGUS
T1625	indication 54056 54059	CHC
T1627	indication 54080 54084	CHC/
T1629	tradename 54327 54334	PEGASYS
T1631	co-administereddrug 54364 54372	COPEGUS.
T1633	indication 54453 54456	CHC
T1635	indication 54546 54549	CHC
T1637	tradename 54712 54719	PEGASYS
T1639	co-administereddrug 54749 54757	COPEGUS.
T1641	indication 54874 54893	Chronic Hepatitis C
T1643	indication 54925 54936	hepatitis C
T1645	adversereaction 55131 55149	hyperbilirubinemia
T1647	adversereaction 55224 55257	Liver function test abnormalities
T1649	adversereaction 55312 55332	autoimmune hepatitis
T1651	indication 55430 55449	Chronic Hepatitis B
T1653	adversereaction 55450 55474	Transient ALT elevations
T1655	indication 55493 55504	hepatitis B
T1657	tradename 55518 55526	PEGASYS.
T1659	tradename 56326 56333	PEGASYS
T1661	tradename 56360 56367	PEGASYS
T1663	co-administereddrug 56397 56404	COPEGUS
T1665	indication 56541 56552	hepatitis C
T1667	tradename 56678 56685	PEGASYS
T1669	tradename 56720 56727	PEGASYS
T1671	co-administereddrug 56732 56739	COPEGUS
T1673	tradename 56851 56858	PEGASYS
T1675	tradename 57449 57456	PEGASYS
T1677	dose 57457 57471	180 mcg/1.73 m
T1679	co-administereddrug 57480 57487	COPEGUS
T1681	dose 57488 57496	15 mg/kg
T1683	tradename 57505 57512	PEGASYS
T1685	dose 57513 57527	180 mcg/1.73 m
T1687	tradename 57553 57560	PEGASYS
T1689	indication 58198 58217	Chronic Hepatitis C
T1691	tradename 58265 58272	PEGASYS
T1693	co-administereddrug 58289 58296	COPEGUS
T1695	activeingredient 58329 58347	interferon alfa-2a
T1697	tradename 58425 58432	PEGASYS
T1699	co-administereddrug 58449 58456	COPEGUS
T1701	indication 58554 58573	Chronic Hepatitis B
T1703	indication 58606 58617	hepatitis B
T1705	tradename 58640 58647	PEGASYS
T1707	activeingredient 58693 58711	interferon alfa-2a
T1709	tradename 58792 58799	PEGASYS
T1711	tradename 59524 59531	PEGASYS
T1713	tradename 59726 59733	PEGASYS
T1715	adversereaction 59984 60005	pure red cell aplasia
T1717	adversereaction 60036 60054	hearing impairment
T1719	adversereaction 60056 60068	hearing loss
T1721	adversereaction 60098 60117	tongue pigmentation
T1723	adversereaction 60144 60165	Liver graft rejection
T1725	adversereaction 60170 60191	renal graft rejection
T1727	adversereaction 60269 60280	dehydration
T1729	adversereaction 60322 60344	serious skin reactions
T1731	adversereaction 60360 60368	seizures
T1733	tradename 60571 60578	PEGASYS
T1735	tradename 60743 60750	PEGASYS
T1737	tradename 61013 61021	PEGASYS.
T1739	co-administereddrug 61027 61036	Methadone
T1741	co-administereddrug 61092 61101	methadone
T1743	tradename 61118 61125	PEGASYS
T1745	co-administereddrug 61355 61364	methadone
T1747	co-administereddrug 61430 61439	methadone
T1749	tradename 61444 61451	PEGASYS
T1751	tradename 61473 61480	PEGASYS
T1753	indication 61486 61505	chronic hepatitis C
T1755	dose 61554 61561	180 mcg
T1757	tradename 61562 61569	PEGASYS
T1759	routeofadministration 61570 61584	subcutaneously
T1761	co-administereddrug 61621 61630	methadone
T1763	dose 61664 61669	95 mg
T1765	dose 61677 61693	30 mg to 150 mg)
T1767	tradename 61713 61721	PEGASYS.
T1769	co-administereddrug 61727 61736	methadone
T1771	tradename 61791 61798	PEGASYS
T1773	co-administereddrug 61834 61843	Methadone
T1775	tradename 61882 61889	PEGASYS
T1777	indication 61921 61940	chronic hepatitis C
T1779	co-administereddrug 61964 61974	methadone.
T1781	indication 62029 62033	CHC/
T1783	tradename 62200 62208	PEGASYS/
T1785	co-administereddrug 62208 62217	ribavirin
T1787	tradename 62540 62547	PEGASYS
T1789	co-administereddrug 62549 62558	ribavirin
T1791	co-administereddrug 62712 62722	Zidovudine
T1793	co-administereddrug 62766 62776	zidovudine
T1795	tradename 62797 62805	PEGASYS/
T1797	co-administereddrug 62805 62812	COPEGUS
T1799	adversereaction 62830 62841	neutropenia
T1801	adversereaction 62883 62889	anemia
T1803	co-administereddrug 62972 62982	zidovudine
T1805	adversereaction 62984 62995	neutropenia
T1807	adversereaction 63009 63015	anemia
T1809	co-administereddrug 63047 63057	zidovudine
T1811	tradename 63142 63149	PEGASYS
T1813	co-administereddrug 63151 63160	ribavirin
T1815	adversereaction 63252 63274	hepatic decompensation
T1817	tradename 63406 63413	PEGASYS
T1819	tradename 63529 63536	PEGASYS
T1821	tradename 63550 63557	PEGASYS
T1823	activeingredient 63621 63639	interferon alfa-2a
T1825	tradename 63864 63871	PEGASYS
T1827	tradename 63976 63983	PEGASYS
T1829	tradename 64003 64010	PEGASYS
T1831	tradename 64115 64122	PEGASYS
T1833	co-administereddrug 64279 64288	Ribavirin
T1835	co-administereddrug 64424 64434	ribavirin.
T1837	co-administereddrug 64435 64444	Ribavirin
T1839	co-administereddrug 64613 64622	ribavirin
T1841	co-administereddrug 64635 64644	Ribavirin
T1843	co-administereddrug 64668 64677	Ribavirin
T1845	co-administereddrug 64839 64848	ribavirin
T1847	tradename 65378 65386	PEGASYS.
T1849	tradename 65439 65446	PEGASYS
T1851	tradename 65513 65520	PEGASYS
T1853	inactiveingredient 65530 65545	benzyl alcohol.
T1855	inactiveingredient 65571 65585	benzyl alcohol
T1857	tradename 65882 65889	PEGASYS
T1859	co-administereddrug 65919 65926	COPEGUS
T1861	adversereaction 66115 66118	CNS
T1863	adversereaction 66120 66127	cardiac
T1865	adversereaction 66129 66147	and systemic (e.g.
T1867	adversereaction 66149 66166	flu-like) effects
T1869	tradename 66247 66254	PEGASYS
T1871	tradename 66275 66282	PEGASYS
T1873	tradename 66577 66584	PEGASYS
T1875	tradename 66696 66703	PEGASYS
T1877	indication 66882 66907	Chronic hepatitis C (CHC)
T1879	adversereaction 66950 66972	hepatic decompensation
T1881	tradename 67030 67038	PEGASYS.
T1883	tradename 67138 67145	PEGASYS
T1885	indication 67296 67315	Chronic hepatitis B
T1887	adversereaction 67337 67390	transient acute exacerbations (flares) of hepatitis B
T1889	tradename 67473 67480	PEGASYS
T1891	tradename 67695 67702	PEGASYS
T1893	tradename 67796 67803	PEGASYS
T1895	co-administereddrug 67808 67815	COPEGUS
T1897	indication 67822 67825	CHC
T1899	tradename 68075 68082	PEGASYS
T1901	dose 68113 68120	135 mcg
T1903	frequency 68121 68133	once weekly.
T1905	tradename 68181 68188	PEGASYS
T1907	tradename 68197 68212	PEGASYS-related
T1909	adversereaction 68239 68246	anemia)
T1911	tradename 68348 68355	PEGASYS
T1913	tradename 68363 68378	PEGASYS-related
T1915	tradename 68442 68449	PEGASYS
T1917	tradename 68537 68544	PEGASYS
T1919	dose 68545 68552	180 mcg
T1921	frequency 68553 68565	once weekly.
T1923	tradename 68566 68573	PEGASYS
T1925	tradename 68912 68920	PEGASYS.
T1927	tradename 69480 69487	PEGASYS
T1929	tradename 69606 69613	PEGASYS
T1931	tradename 69789 69797	PEGASYS.
T1933	indication 69803 69822	Chronic Hepatitis B
T1935	tradename 69850 69857	PEGASYS
T1937	indication 69890 69901	Hepatitis B
T1939	indication 69940 69951	Hepatitis C
T1941	tradename 70186 70193	PEGASYS
T1943	dose 70195 70202	180 mcg
T1945	frequency 70202 70218	/day for 7 days)
T1947	frequency 70279 70285	Weekly
T1949	dose 70301 70308	630 mcg
T1951	adversereaction 70387 70394	fatigue
T1953	adversereaction 70396 70418	elevated liver enzymes
T1955	adversereaction 70420 70431	neutropenia
T1957	adversereaction 70437 70454	thrombocytopenia.
T1959	tradename 70489 70497	PEGASYS.
T1961	tradename 70571 70578	PEGASYS
T1963	nanoparticle 70580 70601	peginterferon alfa-2a
T1965	activeingredient 70630 70660	recombinant alfa-2a interferon
T1967	molecularweight 70696 70698	20
T1969	molecularweight 70699 70711	000 daltons)
T1971	surfacecoating 70735 70776	bis-monomethoxy polyethylene glycol (PEG)
T1973	molecularweight 70799 70801	40
T1975	molecularweight 70802 70814	000 daltons)
T1977	surfacecoating 70820 70823	PEG
T1979	activeingredient 70865 70880	interferon alfa
T1981	nanoparticle 70923 70944	Peginterferon alfa-2a
T1983	molecularweight 70984 70986	60
T1985	molecularweight 70987 70999	000 daltons.
T1987	activeingredient 71000 71018	Interferon alfa-2a
T1989	tradename 71167 71174	PEGASYS
T1991	routeofadministration 71267 71282	subcutaneously.
T1993	dose 71297 71305	180 mcg/
T1995	nanoparticle 71308 71329	peginterferon alfa-2a
T1997	activeingredient 71358 71377	interferon alfa-2a)
T1999	inactiveingredient 71392 71403	acetic acid
T2001	inactiveingredient 71415 71429	benzyl alcohol
T2003	inactiveingredient 71439 71453	polysorbate 80
T2005	inactiveingredient 71465 71490	sodium acetate trihydrate
T2007	inactiveingredient 71506 71521	sodium chloride
T2009	nanoparticle 71586 71607	peginterferon alfa-2a
T2011	activeingredient 71636 71655	interferon alfa-2a)
T2013	inactiveingredient 71670 71681	acetic acid
T2015	inactiveingredient 71695 71709	benzyl alcohol
T2017	inactiveingredient 71718 71732	polysorbate 80
T2019	inactiveingredient 71745 71770	sodium acetate trihydrate
T2021	inactiveingredient 71788 71803	sodium chloride
T2023	dose 71855 71863	180 mcg/
T2025	nanoparticle 71870 71890	peginteferon alfa-2a
T2027	activeingredient 71919 71938	interferon alfa-2a)
T2029	inactiveingredient 71954 71965	acetic acid
T2031	inactiveingredient 71979 71993	benzyl alcohol
T2033	inactiveingredient 72002 72016	polysorbate 80
T2035	inactiveingredient 72029 72054	sodium acetate trihydrate
T2037	inactiveingredient 72072 72087	sodium chloride
T2039	nanoparticle 72154 72174	peginteferon alfa-2a
T2041	activeingredient 72203 72222	interferon alfa-2a)
T2043	inactiveingredient 72238 72249	acetic acid
T2045	inactiveingredient 72263 72279	benzyl alcohol (
T2047	inactiveingredient 72286 72300	polysorbate 80
T2049	inactiveingredient 72313 72338	sodium acetate trihydrate
T2051	inactiveingredient 72356 72371	sodium chloride
T2053	dose 72535 72550	180 or 135 mcg)
T2055	routeofadministration 72711 72723	subcutaneous
T2057	nanoparticle 72797 72843	Pegylated recombinant human interferon alfa-2a
T2059	tradename 72949 72956	PEGASYS
T2061	dose 73206 73219	90 to 270 mcg
T2063	tradename 73223 73231	PEGASYS.
T2065	tmax 73282 73296	72 to 96 hours
T2067	frequency 73551 73562	once weekly
T2069	tradename 73681 73688	PEGASYS
T2071	clearance 73693 73700	94 mL/h
T2073	activeingredient 73754 73772	interferon alfa-2a
T2075	routeofadministration 73820 73832	subcutaneous
T2077	indication 73857 73876	chronic hepatitis C
T2079	plasmahalflife 73881 73890	160 hours
T2081	plasmahalflife 73898 73914	84 to 353 hours)
T2083	plasmahalflife 73927 73934	5 hours
T2085	plasmahalflife 73942 73959	3.7 to 8.5 hours)
T2087	tradename 74011 74018	PEGASYS
T2089	auc 74131 74151	1295 to 1663 ng-h/mL
T2091	dose 74191 74198	180 mcg
T2093	tradename 74199 74206	PEGASYS
T2095	cmax 74246 74261	9 vs. 10 ng/mL)
T2097	indication 74401 74404	CHC
T2099	tradename 74414 74421	PEGASYS
T2101	dose 74475 74491	180 mcg/1.73 m2)
T2103	tradename 74511 74518	PEGASYS
T2105	dose 74724 74731	180 mcg
T2107	dose 75058 75065	180 mcg
T2109	indication 75128 75131	CHC
T2111	tradename 75392 75399	PEGASYS
T2113	dose 75400 75407	180 mcg
T2115	frequency 75408 75419	once weekly
T2117	nanoparticle 75443 75464	peginterferon alfa-2a
T2119	tradename 75607 75615	PEGASYS.
T2121	tradename 75620 75627	PEGASYS
T2123	nanoparticle 75829 75850	peginterferon alfa-2a
T2125	dose 75954 75961	135 mcg
T2127	frequency 75962 75973	once weekly
T2129	tradename 75974 75981	PEGASYS
T2131	nanoparticle 76074 76095	peginterferon alfa-2a
T2133	dose 76322 76328	90 mcg
T2135	frequency 76329 76340	once weekly
T2137	tradename 76481 76488	PEGASYS
T2139	dose 76519 76526	135 mcg
T2141	frequency 76527 76539	once weekly.
T2143	nanoparticle 76566 76587	peginterferon alfa-2a
T2145	nanoparticle 76696 76717	peginterferon alfa-2a
T2147	dose 76727 76734	135 mcg
T2149	tradename 76818 76825	PEGASYS
T2151	dose 76861 76868	135 mcg
T2153	frequency 76869 76880	once weekly
T2155	dose 77103 77109	90 mcg
T2157	frequency 77110 77121	once weekly
T2159	tradename 77280 77287	PEGASYS
T2161	activeingredient 77308 77342	recombinant human interferon -2a
T2163	nanoparticle 77351 77370	Peginterferon -2a
T2165	activeingredient 77630 77646	interferon -2a
T2167	nanoparticle 77741 77760	peginterferon -2a
T2169	nanoparticle 77921 77934	PEG-IFN -2a
T2171	nanoparticle 78020 78033	PEG-IFN -2a
T2173	co-administereddrug 78038 78047	ribavirin
T2175	co-administereddrug 78232 78241	ribavirin
T2177	co-administereddrug 78406 78415	ribavirin
T2179	tradename 78540 78547	PEGASYS
T2181	tradename 78727 78734	PEGASYS
T2183	tradename 78772 78779	PEGASYS
T2185	tradename 79120 79127	PEGASYS
T2187	tradename 79179 79186	PEGASYS
T2189	routeofadministration 79312 79324	subcutaneous
T2191	dose 79339 79350	600 mcg/kg/
T2193	dose 79356 79368	7200 mcg/m2/
T2195	tradename 79377 79384	PEGASYS
T2197	frequency 79385 79414	every other day for one month
T2199	tradename 79680 79687	PEGASYS
T2201	frequency 79778 79793	Every other day
T2203	dose 79806 79816	100 mcg/kg
T2205	dose 79818 79830	1200 mcg/m2)
T2207	tradename 79831 79838	PEGASYS
T2209	tradename 79986 79993	PEGASYS
T2211	activeingredient 80141 80159	interferon alfa-2a
T2213	dose 80188 80202	25 x 106 IU/kg
T2215	frequency 80202 80207	/day.
T2217	tradename 80340 80347	PEGASYS
T2219	indication 80401 80420	Chronic Hepatitis C
T2221	tradename 80443 80451	PEGASYS/
T2223	co-administereddrug 80451 80458	COPEGUS
T2225	tradename 80526 80533	PEGASYS
T2227	co-administereddrug 80554 80561	COPEGUS
T2229	indication 80583 80594	hepatitis C
T2231	tradename 81066 81073	PEGASYS
T2233	dose 81074 81081	180 mcg
T2235	routeofadministration 81082 81094	subcutaneous
T2237	frequency 81095 81106	once weekly
T2239	routeofadministration 81115 81119	oral
T2241	tradename 81129 81136	PEGASYS
T2243	dose 81137 81144	180 mcg
T2245	frequency 81145 81156	once weekly
T2247	co-administereddrug 81162 81169	COPEGUS
T2249	dose 81170 81177	1000 mg
T2251	routeofadministration 81178 81186	by mouth
T2253	dose 81220 81227	1200 mg
T2255	routeofadministration 81228 81236	by mouth
T2257	dose 81314 81319	3 MIU
T2259	routeofadministration 81320 81332	subcutaneous
T2261	frequency 81333 81351	three times a week
T2263	co-administereddrug 81357 81366	ribavirin
T2265	dose 81367 81374	1000 mg
T2267	dose 81378 81385	1200 mg
T2269	routeofadministration 81386 81395	by mouth)
T2271	co-administereddrug 81489 81496	COPEGUS
T2273	tradename 81657 81664	PEGASYS
T2275	co-administereddrug 81685 81692	COPEGUS
T2277	tradename 81730 81737	PEGASYS
T2279	co-administereddrug 81770 81779	ribavirin
T2281	co-administereddrug 81993 82002	Ribavirin
T2283	dose 82003 82010	1000 mg
T2285	dose 82014 82021	1200 mg
T2287	tradename 82023 82030	PEGASYS
T2289	tradename 82042 82049	PEGASYS
T2291	co-administereddrug 82052 82059	COPEGUS
T2293	dose 82060 82067	1000 mg
T2295	dose 82071 82078	1200 mg
T2297	tradename 82287 82295	PEGASYS/
T2299	co-administereddrug 82295 82302	COPEGUS
T2301	co-administereddrug 82349 82359	ribavirin)
T2303	tradename 82437 82444	PEGASYS
T2305	dose 82445 82452	180 mcg
T2307	routeofadministration 82453 82465	subcutaneous
T2309	frequency 82466 82477	once weekly
T2311	co-administereddrug 82546 82553	COPEGUS
T2313	dose 82569 82575	800 mg
T2315	dose 82579 82594	1000 mg/1200 mg
T2317	tradename 83049 83056	PEGASYS
T2319	dose 83061 83068	1000 mg
T2321	dose 83072 83079	1200 mg
T2323	co-administereddrug 83083 83090	COPEGUS
T2325	dose 83254 83260	800 mg
T2327	co-administereddrug 83261 83269	COPEGUS.
T2329	tradename 83376 83383	PEGASYS
T2331	dose 83388 83394	800 mg
T2333	co-administereddrug 83398 83405	COPEGUS
T2335	dose 83479 83486	1000 mg
T2337	dose 83490 83497	1200 mg
T2339	co-administereddrug 83501 83508	COPEGUS
T2341	tradename 83730 83737	PEGASYS
T2343	co-administereddrug 83740 83747	COPEGUS
T2345	dose 83748 83754	800 mg
T2347	tradename 83764 83771	PEGASYS
T2349	co-administereddrug 83774 83781	COPEGUS
T2351	dose 83782 83789	1000 mg
T2353	dose 83793 83801	1200 mg*
T2355	tradename 83811 83818	PEGASYS
T2357	co-administereddrug 83821 83828	COPEGUS
T2359	dose 83829 83835	800 mg
T2361	tradename 83845 83852	PEGASYS
T2363	co-administereddrug 83855 83862	COPEGUS
T2365	dose 83863 83870	1000 mg
T2367	dose 83874 83882	1200 mg*
T2369	dose 84079 84086	1000 mg
T2371	dose 84120 84127	1200 mg
T2373	nanoparticle 84299 84325	pegylated interferon alpha
T2375	indication 85487 85506	chronic hepatitis C
T2377	co-administereddrug 85575 85582	COPEGUS
T2379	dose 85597 85605	15 mg/kg
T2381	frequency 85605 85609	/day
T2383	tradename 85615 85622	PEGASYS
T2385	dose 85623 85638	180 mcg/1.73 m2
T2387	frequency 85659 85670	once weekly
T2389	co-administereddrug 85948 85955	COPEGUS
T2391	tradename 85961 85968	PEGASYS
T2393	tradename 85972 85979	PEGASYS
T2395	tradename 86010 86017	PEGASYS
T2397	co-administereddrug 86076 86083	COPEGUS
T2399	tradename 86089 86097	PEGASYS.
T2401	co-administereddrug 86221 86228	COPEGUS
T2403	tradename 86234 86241	PEGASYS
T2405	tradename 86258 86265	PEGASYS
T2407	tradename 86536 86552	PEGASYS PEGASYS
T2409	dose 86555 86569	180 mcg/1.73 m
T2411	dose 86580 86594	180 mcg/1.73 m
T2413	co-administereddrug 86614 86621	COPEGUS
T2415	dose 86622 86630	15 mg/kg
T2417	indication 87027 87046	Chronic Hepatitis C
T2419	tradename 87091 87098	PEGASYS
T2421	tradename 87115 87123	PEGASYS/
T2423	co-administereddrug 87123 87130	COPEGUS
T2425	indication 87177 87181	CHC/
T2427	tradename 87219 87226	PEGASYS
T2429	dose 87227 87234	180 mcg
T2431	routeofadministration 87235 87247	subcutaneous
T2433	routeofadministration 87268 87272	oral
T2435	tradename 87282 87289	PEGASYS
T2437	dose 87290 87297	180 mcg
T2439	frequency 87298 87309	once weekly
T2441	co-administereddrug 87315 87322	COPEGUS
T2443	dose 87323 87329	800 mg
T2445	routeofadministration 87330 87338	by mouth
T2447	frequency 87339 87344	daily
T2449	activeingredient 87359 87378	interferon alfa-2a)
T2451	dose 87380 87385	3 MIU
T2453	routeofadministration 87386 87398	subcutaneous
T2455	frequency 87399 87417	three times a week
T2457	co-administereddrug 87423 87430	COPEGUS
T2459	dose 87431 87437	800 mg
T2461	routeofadministration 87438 87446	by mouth
T2463	frequency 87447 87453	daily.
T2465	co-administereddrug 87591 87598	COPEGUS
T2467	tradename 87650 87657	PEGASYS
T2469	indication 87788 87807	chronic hepatitis C
T2471	indication 88231 88250	Chronic Hepatitis C
T2473	co-administereddrug 88294 88301	COPEGUS
T2475	dose 88302 88308	800 mg
T2477	tradename 88318 88325	PEGASYS
T2479	tradename 88345 88352	PEGASYS
T2481	co-administereddrug 88355 88362	COPEGUS
T2483	dose 88363 88369	800 mg
T2485	indication 88561 88565	CHC/
T2487	nanoparticle 88695 88721	pegylated interferon alpha
T2489	tradename 89046 89053	PEGASYS
T2491	co-administereddrug 89058 89067	ribavirin
T2493	indication 89120 89123	CHC
T2495	tradename 89179 89186	PEGASYS
T2497	co-administereddrug 89216 89225	ribavirin
T2499	indication 89351 89370	Chronic Hepatitis C
T2501	tradename 89393 89400	PEGASYS
T2503	tradename 89445 89452	PEGASYS
T2505	indication 89474 89485	hepatitis C
T2507	routeofadministration 89805 89817	subcutaneous
T2509	activeingredient 90173 90192	interferon alfa-2a)
T2511	dose 90193 90198	3 MIU
T2513	frequency 90199 90217	three times a week
T2515	tradename 90219 90226	PEGASYS
T2517	dose 90227 90234	135 mcg
T2519	frequency 90235 90246	once weekly
T2521	tradename 90250 90257	PEGASYS
T2523	dose 90258 90265	180 mcg
T2525	frequency 90266 90278	once weekly.
T2527	dose 90335 90340	6 MIU
T2529	frequency 90341 90372	three times a week for 12 weeks
T2531	dose 90385 90390	3 MIU
T2533	frequency 90391 90422	three times a week for 36 weeks
T2535	tradename 90426 90433	PEGASYS
T2537	dose 90434 90441	180 mcg
T2539	frequency 90442 90454	once weekly.
T2541	dose 90504 90509	3 MIU
T2543	frequency 90510 90528	three times a week
T2545	tradename 90530 90537	PEGASYS
T2547	dose 90538 90544	90 mcg
T2549	frequency 90545 90556	once weekly
T2551	tradename 90560 90567	PEGASYS
T2553	dose 90568 90575	180 mcg
T2555	frequency 90576 90591	once each week.
T2557	tradename 90630 90637	PEGASYS
T2559	dose 90638 90645	180 mcg
T2561	tradename 90937 90944	PEGASYS
T2563	dose 90945 90952	135 mcg
T2565	dose 90988 90996	180 mcg.
T2567	tradename 91021 91028	PEGASYS
T2569	dose 91029 91035	90 mcg
T2571	tradename 91061 91068	PEGASYS
T2573	dose 91069 91076	180 mcg
T2575	dose 91180 91185	3 MIU
T2577	tradename 91195 91202	PEGASYS
T2579	dose 91203 91210	180 mcg
T2581	dose 91246 91253	6/3 MIU
T2583	tradename 91273 91280	PEGASYS
T2585	dose 91281 91288	180 mcg
T2587	dose 91324 91329	3 MIU
T2589	tradename 91338 91345	PEGASYS
T2591	dose 91346 91353	180 mcg
T2593	tradename 91607 91614	PEGASYS
T2595	dose 91671 91706	6 million international units (MIU)
T2597	frequency 91707 91748	three times a week for the first 12 weeks
T2599	dose 91761 91784	3 million international
T2601	dose 91786 91791	units
T2603	frequency 91792 91823	three times a week for 36 weeks
T2605	routeofadministration 91830 91845	subcutaneously.
T2607	tradename 92338 92345	PEGASYS
T2609	dose 92346 92353	180 mcg
T2611	tradename 92517 92524	PEGASYS
T2613	indication 92689 92708	Chronic Hepatitis B
T2615	tradename 92727 92734	PEGASYS
T2617	tradename 92779 92786	PEGASYS
T2619	indication 92808 92827	chronic hepatitis B
T2621	indication 92943 92963	chronic hepatitis B.
T2623	tradename 92993 93000	PEGASYS
T2625	dose 93001 93008	180 mcg
T2627	routeofadministration 93009 93021	subcutaneous
T2629	frequency 93022 93033	once weekly
T2631	tradename 93035 93042	PEGASYS
T2633	dose 93043 93050	180 mcg
T2635	routeofadministration 93051 93063	subcutaneous
T2637	frequency 93064 93075	once weekly
T2639	co-administereddrug 93090 93100	lamivudine
T2641	dose 93101 93107	100 mg
T2643	frequency 93108 93118	once daily
T2645	routeofadministration 93119 93127	by mouth
T2647	co-administereddrug 93131 93141	lamivudine
T2649	dose 93142 93148	100 mg
T2651	frequency 93149 93159	once daily
T2653	routeofadministration 93160 93169	by mouth.
T2655	tradename 93303 93310	PEGASYS
T2657	tradename 93317 93324	PEGASYS
T2659	indication 93402 93421	chronic hepatitis B
T2661	tradename 93842 93849	PEGASYS
T2663	tradename 94080 94087	PEGASYS
T2665	tradename 94117 94124	PEGASYS
T2667	tradename 95016 95023	PEGASYS
T2669	tradename 95113 95120	PEGASYS
T2671	tradename 95222 95229	PEGASYS
T2673	tradename 95290 95297	PEGASYS
T2675	tradename 95578 95585	PEGASYS
T2677	tradename 95711 95718	PEGASYS
T2679	tradename 96090 96097	PEGASYS
T2681	tradename 96178 96185	PEGASYS
T2683	tradename 96281 96288	PEGASYS
T2685	tradename 96349 96356	PEGASYS
T2687	tradename 96456 96463	PEGASYS
T2689	tradename 96561 96568	PEGASYS
T2691	tradename 96711 96718	PEGASYS
T2693	tradename 97578 97585	PEGASYS
T2695	co-administereddrug 97883 97892	ribavirin
T2697	co-administereddrug 97983 97992	Ribavirin
T2699	co-administereddrug 98351 98360	ribavirin
T2701	co-administereddrug 98895 98904	ribavirin
T2703	co-administereddrug 99015 99024	Ribavirin
T2705	tradename 99544 99551	PEGASYS
T2707	tradename 99724 99731	PEGASYS
T2709	indication 99936 99947	hepatitis C
T2711	indication 100052 100063	hepatitis C
T2713	tradename 100563 100570	PEGASYS
T2715	tradename 101171 101179	PEGASYS.
T2717	tradename 101342 101349	PEGASYS
T2719	tradename 102510 102517	PEGASYS
T2721	company 102536 102558	Hoffmann-La Roche Inc.
T2723	company 102577 102594	Hoffmann-La Roche
T2725	company 102596 102600	Inc.
T2727	company 102605 102614	Genentech
T2729	company 102616 102620	Inc.
T2731	company 102637 102648	Roche Group
T2733	company 102711 102724	Genentech USA
T2735	company 102726 102730	Inc.
T2737	company 102747 102758	Roche Group
T2739	company 102810 102819	Genentech
T2741	company 102821 102825	Inc.
